Evidence map›Paper›PMID 21909901›Full record

ArticleDer Internist2011

[Arterial occlusive disease. Catheter-directed thrombolytic therapy].

C Stelzner, R Langhoff

Abstract readEnglish Abstract
PubMed Publisher
In one paragraph

Article in Der Internist, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

C StelznerAbteilung für Angiologie, Medizinische Klinik 2, Städtisches Klinikum Dresden-Friedrichstadt, Akademisches Lehrkrankenhaus, Technische Universität Dresden, Friedrichstr. 41, 01067, Dresden. stelzner-ch@khdf.de
R Langhoff

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Local catheter-directed thrombolysis of extremity artery or bypass thromboembolic occlusions is a promising therapeutic option with comparatively low complication rates, if the severity of the ischemia does not require urgent surgical revascularization. This therapeutic decision has to be made by a vascular team taking individual circumstances and contraindications into consideration. Apart from an adequate dosage, a strict intrathrombotic administration of the fibrinolytic agent and careful clinical monitoring including surveillance of the coagulation system is necessary and intensive care unit resources should be used. If necessary the thrombolysis therapy can be combined with mechanical thrombaspiration and balloon dilatation or surgical correction of an underlying lesion.

Indexed as

AnticoagulantsArterial Occlusive DiseasesCatheterization, PeripheralFibrinolytic AgentsHumansThrombectomyThrombolytic TherapyThrombosisAnticoagulantsFibrinolytic Agents

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.